Furthermore, our studies will identify differences in gut microbiome and fecal bacteria inducing IgA responses, and assess the association of specific IgA immune responses with clinical tolerance, i.e., protection from early-onset AD and FA. Here, CD79A is linked to Alzheimer disease.